Huasu Holdings (000509.SZ): The recently disclosed announcement on the progress of the equity acquisition contained revision marks due to an upload error by staff; there was no deliberate concealment or misleading of the market.
Huasu Holdings (000509.SZ) announced that recently, the company disclosed the "Announcement on the Progress of Equity Acquisition and Signing of Equity Transfer Agreement" on Cninfo. Some media outlets have successively published reports since the evening of October 9 regarding the above announcement version containing revision marks, raising market questions about this acquisition announcement and related transaction content. The articles mainly involve: 1. Why did errors occur in the company's information disclosure review process; 2. Whether the revision records involve sensitive or confidential content. Upon verification, the company provides the following explanation regarding the above matters:
Huasu Holdings (000509.SZ) announced that recently, the company disclosed on CNINFO the "Announcement on the Progress of the Equity Acquisition and Signing of the Equity Transfer Agreement." Some media outlets have successively published reports since the evening of October 9 regarding the above announcement version containing revision marks, raising market questions about this acquisition announcement and related transaction content. The articles mainly addressed: 1. Why did errors occur in the company's information disclosure review process; 2. Whether the revision records involved sensitive or confidential content. Upon verification, the company provides the following explanations regarding the above matters:
1. This incident was caused by staff failing to change the announcement file from "Final State" under "Revisions" to "Accept All Revisions to the Document" when uploading the announcement, and reviewers failing to include the version revision status within the scope of their review.
2. The revision records did not involve sensitive or confidential content. The revised version and the final official version are completely identical in content, and there is no discrepancy in the information disclosed:
(1) Regarding the description of the scope of guarantees for the target company, the deleted content was all payment for goods covered by the target company's guarantee agreement, amounting to RMB 15,443,275. The guarantee agreement was signed in May 2025. As of the signing date of this equity transfer agreement, the counterparty has gradually repaid most of the payment for goods, and the book balance of the payment for goods covered by the guarantee is only RMB 3.1055 million. According to the provisions of the Equity Acquisition Agreement, the above guarantee obligations shall be released before the closing of this transaction. After the completion of this transaction, all equipment assets and all income under the name of the target company shall not be subject to mortgage, pledge, seizure, freezing, or other rights restrictions. To avoid misleading investors, the company modified the relevant statements in the announcement to ensure that the final disclosed content is true and accurate.
(2) Regarding the deleted statement that "the agreed repayment period shall not exceed 5 years," since the Repayment Plan Agreement has not been formally signed, it is inappropriate to specify a specific repayment period in the announcement. The company disclosed the future arrangement of intending to sign the Repayment Plan Agreement and specifying the repayment amount and repayment period.
The above revisions represent more rigorous expressions based on the true situation, and there is no deliberate concealment of the guarantee scale, repayment period, or other behavior misleading market judgment. The above revisions have not changed the core terms and established arrangements of this transaction, nor will they have a material impact on the progress of this equity acquisition.
Related Articles

CITIC SEC: Q3 US stock earnings may continue high growth; Hong Kong stock fundamental expectations have entered a bottoming phase.

How to cope with high interest rates? CITIC SEC: Allocate to booming sectors and varieties with supply cleared.

Jinghua Pharmaceutical Group (002349.SZ): Jidesheng Snake Medicine Tablets receives drug clinical trial approval for new herpes zoster indication
CITIC SEC: Q3 US stock earnings may continue high growth; Hong Kong stock fundamental expectations have entered a bottoming phase.

How to cope with high interest rates? CITIC SEC: Allocate to booming sectors and varieties with supply cleared.

Jinghua Pharmaceutical Group (002349.SZ): Jidesheng Snake Medicine Tablets receives drug clinical trial approval for new herpes zoster indication






